Hyperfine (HYPR) said late Tuesday that it enrolled initial patients in a study that will assess the use of portable ultra-low-field magnetic resonance imaging, or MRI, in neurology offices.
The study will compare portable low-field MRI and conventional high-field MRI for pathology findings, clinical utility and patient experience, the company said.
Hyperfine said it plans to enroll 100 patients in the study and complete the trial by year-end.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。